XW033G6
Introduction Peripheral Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 3 Peripheral Vein |
| Approach | 3 Percutaneous |
| Device | G REGN-COV2 Monoclonal Antibody |
| Qualifier | 6 New Technology Group 6 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Peripheral Vein
Peripheral veins are the superficial and deep venous vessels of the extremities and other non-central locations, commonly accessed for intravenous therapy because they are relatively easy to cannulate and carry lower procedural risk than central venous access. Introduction procedures coded here under New Technology involve infusing a novel substance through a peripheral vein into the systemic circulation, distinguishing this route from central venous administration where drug concentration, infusion rate, or vessel size requirements differ. Because peripheral veins have smaller caliber and lower flow rates than central vessels, certain New Technology agents may be formulated or dosed specifically for this route to minimize irritation or infiltration. Accurate coding depends on confirming that the access point was genuinely a peripheral rather than a central vein.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: REGN-COV2 Monoclonal Antibody
REGN-COV2 refers to the casirivimab and imdevimab monoclonal antibody combination developed for treatment of COVID-19, administered to reduce viral load and disease severity in eligible patients, particularly those at risk for progression. It is distinct from tixagevimab and cilgavimab, another COVID-19 antibody combination intended primarily for pre-exposure prophylaxis rather than active infection treatment, reflecting a difference in both target use and antibody composition.
Qualifier: New Technology Group 6
This value marks Group 6, the cohort of new technologies added for the 2019-2020 fiscal year. As with every group qualifier in this section, it is a bookkeeping label showing when a technology earned a distinct code rather than a clue to its function, which is conveyed through the accompanying device or substance value. It should not be read as interchangeable with Group 5 or Group 7.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.